Get UPTO 25% Discount on All Medicines. Use Coupon Code - SAVE25
Opana ER is an extended-release formulation of oxymorphone, a potent opioid analgesic. Opioid extended-release products have important safety considerations and are intended for appropriately selected patients with severe, persistent pain when alternative treatments are inadequate.
Oxymorphone is a Schedule II controlled substance, with recognized risks of misuse, abuse, dependence, overdose, and respiratory depression.
Oxymorphone acts on opioid receptors in the central nervous system and changes the body's perception of pain. Extended-release formulations are designed to provide prolonged analgesic effects rather than rapid, short-term relief.
Because of its potency and extended-release characteristics, dosing needs to be individualized by a qualified healthcare professional.
FDA guidance states that extended-release/long-acting opioids should generally be reserved for severe and persistent pain requiring extended opioid treatment when alternative options are inadequate.
A healthcare professional may first evaluate non-opioid medications, physical therapy, rehabilitation, and other pain-management approaches.
Oxymorphone extended-release products carry serious warnings involving addiction, abuse, misuse, overdose, and potentially fatal respiratory depression. Respiratory depression can occur even when opioids are used as directed and is particularly important when treatment begins or doses are increased.
Patients should never increase their dose independently.
Extended-release opioid tablets must be taken exactly as directed. Altering an extended-release tablet can cause the medication to be released too quickly, potentially producing a dangerously high opioid exposure.
Patients should follow the specific administration instructions provided with their prescription.
Combining opioids with benzodiazepines, alcohol, or other central nervous system depressants can increase the risk of profound sedation and respiratory depression.
Patients should provide their prescriber and pharmacist with a complete list of medications, supplements, and substances they use.
Physical dependence can develop during continued opioid treatment. Abruptly stopping an opioid in a physically dependent patient can produce withdrawal symptoms.
FDA labeling recommends gradual tapering when discontinuation is appropriate rather than sudden cessation.
There is an important distinction between older Opana ER information and current availability. FDA requested removal of reformulated Opana ER from the market in 2017 because of concerns regarding the public-health consequences associated with abuse of the product. FDA subsequently withdrew the relevant approval.
Consequently, consumers should be particularly cautious about websites claiming to offer genuine Opana ER for unrestricted online purchase.
A website advertising “No Rx,” “prescription-free,” one-click opioid purchasing, or guaranteed shipping should not be treated as a legitimate substitute for medical care.
For controlled medications, consumers should use appropriate healthcare and pharmacy channels, verify that a provider is properly licensed, and obtain medication only when legitimately prescribed.
Depending on the underlying condition, pain treatment may involve:
A multimodal approach can sometimes provide effective pain relief while reducing unnecessary opioid exposure.
Oxymorphone extended-release medication is a potent opioid requiring careful professional oversight. Its risks include misuse, addiction, dependence, overdose, and life-threatening respiratory depression.
Anyone considering treatment for severe or persistent pain should discuss the available options with a qualified healthcare professional and obtain prescription medication through legitimate, regulated channels.